Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips In 2020, the race for the Covid-19 vaccine distorted investment inflows in the biotechnology sector. Back then, emerging biotech stocks tripled or more on hopes that they would come out with a vaccine. Buying interest in ...
– Gastroenterology Investor Call to take place on Tuesday, September 21, 2021 at 10:30 a.m. ET – Dermatology Investor Call to take place on Monday, September 27, 2021 at 11:00 a.m. ET Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today anno...
Senate passage of a $1T infrastructure bill gave a boost to steel and construction stocks on Tuesday. Nucor (NYSE:NUE), Alcoa (NYSE:AA) and Summit Materials (NYSE:SUM) all gained ground on the prospects of higher government spending. Fisker (NYSE:FSR) rallied more than 20% on Tuesday, bolster...
Image source: The Motley Fool. Arena Pharmaceuticals, inc (NASDAQ: ARNA) Q2 2021 Earnings Call Aug 5, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Arena Pharmaceuticals, inc (ARNA) Q2 2021 Earnings Call Transcrip...
Arena Pharmaceuticals, Inc. (ARNA) Q2 2021 Earnings Conference Call August 5, 2021 4:30 PM ET Company Participants Patrick Malloy - Vice President, Investor Relations and Corporate Communications Amit Munshi - President and Chief Executive Officer Doug Manion - Executive Vice President of Res...
Arena Pharmaceuticals (NASDAQ:ARNA): Q2 GAAP EPS of -$2.40 misses by $0.22. Cash, cash equivalents and marketable securities of $1B. Phase 3 ELEVATE UC 12 trial reached full enrollment; topline data expected Q1 2022 with ELEVATE UC 52. Press Release For further details see: Arena P...
– Phase 3 ELEVATE UC 12 trial reached full enrollment; topline data expected Q1 2022 with ELEVATE UC 52 – Liquidity position at ~$1.0 billion as of June 30, 2021 to support continued pipeline progress Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today pro...
Second Genome Announces Collaboration with Arena Pharmaceuticals to Identify Gastrointestinal Biomarkers Second Genome to identify microbiome signals for a proof-of-concept study within Arena's CULTIVATE Phase 2/3 clinical trial for Crohn's disease PR Newswire BRIS...
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its second quarter 2021 financial results and provide a corporate update on Thursday, August 5, 2021, after the close of the U.S. financial markets. The Company will host a live webcast to discuss the results with the investmen...
naphtalina/iStock via Getty Images Arena Pharmaceuticals ([[ARNA]] +2.1%) has recovered after a loss of nearly 4% Tuesday that followed an announcement of a strategic collaboration agreement with Aristea Therapeutics. Per the terms, Arena will make a $60M upfront payment to Aristea in ad...
News, Short Squeeze, Breakout and More Instantly...
Arena Pharmaceuticals Inc. Company Name:
ARNA Stock Symbol:
NASDAQ Market:
Arena Pharmaceuticals Inc. Website:
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded at a new 52-week high today of $99.95. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.2 million shares. Arena Pharmaceuticals is a biotechnology company targeting G-protein-couple...
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded today at a new 52-week high of $98.57. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.1 million shares. Over the past year, Arena Pharmaceuticals Inc. has traded in a range of $45...